

Electrocardiographic Changes in Dogs with Degenerative Mitral Valve Disease Treated with Pimobendan: a Retrospective Study of 29 Cases

Sirilak Disatian Surachetpong^{1*} Nisarat Boonlue² Pasorn Pupa² Waratsarin Boonsathithanan²
Sumanee Rakthaidee² Tanawan Mangklabruks³ Siriwan Sakarin⁴

Abstract

The aim of this retrospective study was to evaluate changes in electrocardiograms (ECG) and cardiac arrhythmias in 29 dogs with degenerative mitral valve disease (DMVD) treated with pimobendan chronically. All dogs had normal ECG before pimobendan administration. The dogs were classified according to ECG after pimobendan administration into 2 groups: normal ECG (n=19) and abnormal ECG (n=10). Age, sex, breed, serum alkaline phosphatase, concurrent digoxin administration, total daily dosage of pimobendan and digoxin, duration of pimobendan administration, and ECG parameters including heart rate, P wave, PR interval, QRS complex, and QT interval were analyzed. Cardiac arrhythmias were increasingly found in the dogs treated with pimobendan in combination with digoxin. The total daily dosage of pimobendan and digoxin in the dogs with abnormal ECG was higher than in those with normal ECG ($p=0.022, 0.038$, respectively). In conclusion, cardiac arrhythmias can be found in dogs chronically treated with pimobendan. Therefore, caution should be taken when using pimobendan at a high dosage or in combination with digoxin.

Keywords: arrhythmia, canine, digoxin, pimobendan

¹Department of Veterinary Medicine, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand

²6th year student, Academic year 2014, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand

³Clinic for Small Domestic Animals and Radiology, Faculty of Veterinary Medicine, Mahanakorn University of Technology, Bangkok 10530, Thailand

⁴Master degree student, Academic year 2014, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand

*Correspondence: sirilakd27@gmail.com

Introduction

Several studies in human patients reported that some of the positive inotropic agents might have pro-arrhythmic effects (Felker and O'Connor, 2001; Packer et al., 1991). In veterinary medicine, studies evaluating pro-arrhythmic effects of positive inotropic drugs are scarce. Presently, positive inotropes such as pimobendan and digoxin have been widely prescribed in dogs with congestive heart failure, including the most common disease, degenerative mitral valve disease (DMVD) (Summerfield et al., 2012; Haggstrom et al., 2013^a; Kanno et al., 2007).

Pimobendan (4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone), a benzimidazole-pyridazinone derivative, increases the myocardium contractility by inhibiting phosphodiesterase 3 and 4 enzymes, decreasing an elimination of cyclic adenosine 3',5'-monophosphate (cyclic AMP), and ultimately increasing calcium within the cytosol of the myocardium. Pimobendan also enhances the myocardial contractility without an increase in myocardial oxygen demand by augmenting the sensitivity of troponin C to calcium, which is called the calcium sensitizing property (Fitton and Brogden, 1994). This property of pimobendan is different from cardiac glycosides such as digoxin and catecholamines (Matos and Glaus, 2010). Moreover, pimobendan acts as a vasodilator by increasing the cyclic AMP within the endothelial cells, facilitating calcium uptake through intracellular storage sites, thereby decreasing the amount of calcium available for contraction, resulting in vasodilation (McDaniel et al., 1994). It has been believed that pimobendan has a low calcium-mediated pro-arrhythmic effect because pimobendan acts as a calcium sensitizer with a minimal effect on an increase in calcium concentration in the myocardium (Ruegg, 1986). Nowadays studies evaluating pro-arrhythmic effects of pimobendan are sparse and conflicting. A previous study reported that pimobendan had an acute effect on electrophysiological properties of the myocardium and atrioventricular (AV) node (Kitzen et al., 1988). Human patients treated by pimobendan had a trend toward higher risk of sudden death, presumably secondary to cardiac arrhythmias (Felker and O'Connor, 2001; Lubsen et al., 1996). An adverse effect of pimobendan inducing cardiac arrhythmias in giant dog breeds has been suggested (Rosenthal et al., 2006). Several studies reported evidence of cardiac arrhythmias in dogs treated with pimobendan; however, the frequency and incidence of arrhythmias were not different when compared with dogs treated with the other drug, benazepril (Haggstrom et al., 2008; Haggstrom et al., 2013^a). A short-term pilot study did not find any significant difference in the incidence or types of arrhythmia between degenerative mitral valve disease (DMVD) dogs treated with pimobendan and a placebo (Lake-Bakaar et al., 2015). However, most of these studies were performed over limited time periods, i.e. not more than 2 months, and were not designed for evaluating a pro-arrhythmic effect of pimobendan. To the authors' knowledge, a long-term effect of pimobendan on cardiac arrhythmias in dogs with heart

diseases has not been studied yet. Therefore, the aim of this study was to evaluate long-term effects of pimobendan on electrocardiographic changes and cardiac arrhythmias in dogs affected by DMVD.

Materials and Methods

From February 2010-November 2014, clinical data on dogs diagnosed with DMVD stage C at the Cardiology Clinic, Small Animal Veterinary Teaching Hospital, Chulalongkorn University, Thailand were studied. The dogs had been diagnosed with DMVD by an echocardiographer (SS) and staged using the American College of Veterinary Internal Medicine (ACVIM) classification (Atkins et al., 2009). Echocardiography, radiography, and electrocardiography (ECG) were performed on the day of the DMVD diagnosis before the administration of pimobendan. All the dogs were treated with pimobendan at an average dosage of 0.39 ± 0.15 mg/kg per day. Data on the patients including age, sex, weight, breed, alkaline phosphatase levels, concurrent use of digoxin, total daily dosage of pimobendan and digoxin, duration of pimobendan administration, ECG before and after treatment with pimobendan, and time of pimobendan treatment before the occurrence of arrhythmias were collected. Electrocardiographic records obtained from a three-minute Lead II tracing were evaluated. Duration and amplitude of P wave, QRS complex, and T wave as well as PR and QT intervals were measured randomly and averaged from 10 consecutive waves. QT and corrected QT (QTc) intervals were measured and calculated, using Van de Water's equation $QTc = (QT - 0.087 * [(60 / HR) - 1])$ (Van de Water et al., 1989). Dogs with abnormal ECG prior to pimobendan treatment were excluded from the study. Newly diagnosed cardiac arrhythmias after treatment with pimobendan were recorded.

Statistical analysis

Statistical analyses were performed using a commercial statistical software (Minitab®17, State College, PA, USA). The patient data including age, sex, weight, breed, and alkaline phosphatase levels were reported descriptively. Normality of the data was tested by the Shapiro-Wilk. Normally distributed data were presented as mean \pm standard deviation (SD). In dogs with normal ECG after pimobendan administration, ECG parameters including P wave, QRS complex, T wave durations and amplitudes, and duration of PR and QTc intervals were compared before and after pimobendan treatment by a paired *t* test. Effects of the treatment duration, breeds of dogs, and concurrent use of digoxin on an evidence of ECG abnormalities were evaluated by Fisher's exact test. The dosage per day of pimobendan and digoxin and the treatment duration of dogs with normal and abnormal ECG after pimobendan treatment were compared by an unpaired *t*-test. Differences at *p*-value <0.05 were considered significant.

Results

The data of twenty-nine dogs met the inclusion criteria. Nineteen dogs had normal ECG and ten dogs had abnormal ECG after treated with

pimobendan. The information on the dogs is summarized in Table 1.

In the dogs with normal ECG after treated with pimobendan, there was no difference in the P wave, QRS complex, T wave durations and amplitudes, and duration of PR and QTc intervals before and after being treated with pimobendan alone

(Table 2) and pimobendan in combination with digoxin (Table 3).

The data of dogs with abnormal ECG after being treated with pimobendan are summarized in Table 4. Eight of the ten dogs had increased alkaline phosphatase after being treated with pimobendan. Only three dogs had higher levels more than five times of normal limits.

Table 1 Information on 29 dogs included in the study

	Total dogs (n=29)	Dogs with normal ECG after treated with pimobendan (n=19)	Dogs with abnormal ECG after treated with pimobendan (n=10)
Age (year)*	12.9±2.5	13.3±2.7	12.3±2.2
Weight (Kg)*	7.4±5.6	6.2±4.6	9.6±6.7
Sex	Male=18 (62.1%) Female=11 (37.9%)	Male=11 (57.9%) Female=8 (42.1%)	Male=7 (70.0%) Female=3 (30.0%)
Small breeds	21 (72.4%) Shih Tzu (8), Poodle (7), Miniature pinscher (2), Splitz (1), Pekingese (1), Pomeranian (1), Chihuahua (1)	15 (78.9%) Shih Tzu (6), Poodle (4), Miniature Pinscher (2), Splitz (1), Pekingese (1), Chihuahua (1)	6 (60.0 %) Poodle (3), Shih Tzu (2), Pomeranian (1)
Middle breeds	8 (27.6%) Mixed (6), Bangkeaw (1), Basset hound (1)	4 (21.1%) Mixed (3), Basset hound (1)	4 (4.0%) Mixed (3), Bangkeaw (1)
Digoxin			
Treated	14 (48.3%)	6 (31.6%)	8 (80.0%)
Not treated	15 (51.7%)	13 (68.4%)	2 (20.0%)
Dosage (mg/kg/d)			
Pimobendan	0.39±0.15	0.35±0.15	0.47±0.12
Digoxin (n=14)	0.007±0.002	0.005±0.001 (n=6)	0.008±0.003 (n=8)

*Data presented as mean±standard deviation (SD)

Table 2 Comparison of electrocardiography before and after treated with pimobendan alone in DMVD dogs with normal ECG (n=13)

	Before	After	p-value
Heart rate (b/m)	116±23	126±23	0.12
P wave			
Amplitude (mV)	0.29±0.11	0.26±0.12	0.49
Duration (sec)	0.05±0.01	0.04±0.01	0.16
PR interval (sec)	0.09±0.03	0.10±0.04	0.51
QRS complex			
Amplitude (mV)	1.99±0.95	1.71±0.62	0.30
Duration (sec)	0.04±0.03	0.04±0.06	0.34
QTc interval (sec)	0.16±0.06	0.16±0.08	0.56

Data presented as mean±standard deviation (SD)

Table 3 Comparison of electrocardiography before and after treated with pimobendan in combination with digoxin in dogs with normal ECG (n=6)

	Before	After	p-value
Heart rate (b/m)	134±26	131±21	0.81
P wave			
Amplitude (mV)	0.32±0.09	0.25±0.13	0.39
Duration (sec)	0.04±0.01	0.04±0.01	0.36
PR interval (sec)	0.10±0.03	0.12±0.01	0.61
QRS complex			
Amplitude (mV)	2.08±0.46	1.84±0.58	0.29
Duration (sec)	0.05±0.02	0.04±0.01	0.26
QTc interval (sec)	0.19±0.11	0.18±0.02	0.78

Data presented as mean±standard deviation (SD)

Five dogs were treated with pimobendan for a month. Two out of these dogs had abnormal ECG. Eight of fourteen dogs treated with pimobendan for

more than a month had abnormal ECG. Six of the twenty-one small breeds and four of the eight middle breeds had abnormal ECG. There was no effect of the

treatment duration (30 days versus >30 days) ($p=0.211$) and breed (small versus middle breeds) ($p=0.348$) on the development of abnormal ECG. The duration of pimobendan administration was not different between the dogs with normal ECG (202 ± 47 days) and abnormal ECG (333 ± 74 days) ($p=0.155$). The dogs treated with pimobendan in combination with digoxin

had a higher risk of developing abnormal ECG than the dogs treated with pimobendan alone ($p=0.013$) (Table 1). The dogs with abnormal ECG were treated with a higher dosage per day of digoxin and pimobendan than the dogs with normal ECG ($p=0.038$, $p=0.022$, respectively) (Table 1).

Table 4 Information on dogs with abnormal electrocardiography after treated with pimobendan

Age (year)	Breed	Digoxin	Duration of pimobendan supplementation (month)	Alkaline phosphatase		Electrocardiography		Severe LA enlargement (LA:Ao ratio>2)
				Before	After	Before receiving pimobendan	After receiving pimobendan	
16	Shih Tzu	N	1	254	65	Respiratory arrhythmia	2 nd degree AV block	Y
11	Poodle	N	1	63	104	Sinus rhythm	Atrial fibrillation	Y
11	Bangkeaw	Y	2	102	65	Respiratory arrhythmia	Junctional premature beat	N
13	Mixed	Y	5	19	36	Sinus rhythm	Atrial fibrillation with VPCs	Y
13	Poodle	Y	8	184	353	Sinus rhythm	2 nd degree AV block	N
14	Mixed	Y	10	148	735	Sinus rhythm	Sinus tachycardia*	N
14	Poodle	Y	14	107	223	Sinus rhythm	Sinus tachycardia*	N
11	Mixed	Y	14	86	159	Respiratory arrhythmia	Sinus tachycardia*	N
12	Pomeranian	Y	15	78	190	Sinus rhythm	Atrial fibrillation	N
8	Shih Tzu	Y	16	264	319	Respiratory arrhythmia	Atrial fibrillation	Y

LA=Left atrium; Ao=aorta; Y=yes; N=no

*Sinus tachycardia was defined as heart rate more than 200 beat/min.

Discussion

The major finding of this study is that cardiac arrhythmias can be found in dogs chronically treated with pimobendan, especially in dogs treated with a higher dosage of pimobendan and/or in combination with digoxin.

The earliest time to detect cardiac arrhythmias in the population of dogs in this study was a month after the pimobendan treatment. Types of cardiac arrhythmias included atrial fibrillation, sinus tachycardia, second degree AV block, ventricular premature beat, and junctional premature beat. These arrhythmias were similar to the evaluation study of safety and effectiveness of pimobendan (Vetmedin, 2007). The majority of dogs with cardiac arrhythmias in the present study had atrial fibrillation. The mechanism of pimobendan-induced atrial fibrillation has not been reported. Severe left atrial enlargement may be a potential cause of atrial fibrillation in 3 of 4 dogs in the present study. It is possible that atrial fibrillation may occur secondarily to the disease progression rather than being a direct effect of pimobendan itself. Pimobendan has a dose-dependent increase in heart rate secondary to an increase in intracellular cAMP in cardiac tissues (Hagemeijer, 1993; Chu et al., 1995). One study reported severe sinus tachycardia in dogs administered with a high dose of pimobendan (Reinker et al., 2012). Three dogs in the

present study had sinus tachycardia (heart rate >200 beats/min) after approximately a year of treatment with pimobendan. In contrast, several studies failed to report the evidence of pimobendan-induced sinus tachycardia (Smith et al., 2006; Haggstrom et al., 2013b). Second degree AV block and junctional premature beat in three dogs in the present study may occur secondarily to the effect of pimobendan on function of the AV node (Kitzen et al., 1988). One dog in the present study had ventricular premature complex (VPC). It has been concerned that phosphodiesterase III inhibitors like pimobendan may exacerbate the development of ventricular arrhythmias (Lynch et al., 1988; Rosenthal et al., 2006). However, a recent study could not find difference in VPCs number/24 h between dogs treated with pimobendan and a placebo (Lake-Bakaar et al., 2015). Several studies demonstrated that there was no difference in VPC numbers and incidence of ventricular arrhythmias when compared between dogs treated with pimobendan and angiotensin converting enzyme (ACE) inhibitors (Smith et al., 2006; O'Grady et al., 2004). Based on the results of those previous studies, the effect of pimobendan-induced VPCs is still controversial. In the present study, some dogs with abnormal ECG had high levels of alkaline phosphatase after being treated with pimobendan. According to the safety study, pimobendan can cause a mild elevation of alkaline phosphatase levels (Vetmedin, 2007). It has

been suggested that alkaline phosphatase may increase due to a major elimination pathway of pimobendan through bile excretion (Plumb, 2008).

Presently, there are few studies determining the pro-arrhythmic effects of pimobendan in veterinary medicine. A previous study showed that dogs treated with higher doses of pimobendan had a higher risk of developing cardiac arrhythmias (Summerfield et al., 2012). Similarly, the present study showed that the dogs with abnormal ECG were treated with a higher dosage of pimobendan than those with normal ECG. However, the present study failed to show the effect of breed (small versus medium breeds) on pimobendan-induced cardiac arrhythmias. A previous study showed that giant dog breeds had a higher risk of developing cardiac arrhythmias after treatment with pimobendan (Rosenthal et al., 2006). Unfortunately, none of the giant breeds was included in the present study.

The dogs treated with pimobendan in combination with digoxin had a higher risk of developing cardiac arrhythmias than those treated with pimobendan alone. The dogs with cardiac arrhythmias were also treated with a higher dosage of digoxin. Digoxin itself can cause cardiac arrhythmias secondary to its toxicity (Steiness and Olesen, 1976). However, all dogs developing cardiac arrhythmias in this study had digoxin levels (1.5 ± 0.5 ng/ml) within the normal limit (0.5-2 ng/ml) and presented no sign of digoxin toxicity, e.g. diarrhea, anorexia, and vomiting. Presently, there was no report studying the synergist effect of pimobendan and digoxin on induced cardiac arrhythmias. In theory, pimobendan may increase the rate of intestinal digoxin absorption (Aiba et al., 2005). However, clinically, there is no report evaluating the effects of pimobendan on digoxin absorption or serum digoxin concentration.

Because the study was retrospective, there were several limitations that could not be controlled. Firstly, the present study was performed without a control group; thus, the effect of worsening disease severity was not accounted for. Arrhythmias might develop without the effects of pimobendan. Secondly, the monthly follow-up might delay or miss the detection of cardiac arrhythmias in some dogs before the appointment. Thirdly, the data were collected from a small number of dogs, not enough to extrapolate the whole population of dogs. Thus, a prospective study evaluating the long-term effect of pimobendan on ECG changes and electrophysiology with a larger number of dogs should be performed. Lastly, Holter monitoring was not done in the present study. With 3-minute ECG tracings, cardiac paroxysmal arrhythmias might not be detected in some dogs.

In conclusion, cardiac arrhythmias may develop in some dogs treated chronically with pimobendan, especially in dogs treated with a higher dosage of pimobendan and/or in combination with digoxin. ECG monitoring should be performed in dogs chronically administered with pimobendan.

References

Aiba T, Ishida K, Yoshinaga M, Okuno M and Hashimoto Y. 2005. Pharmacokinetic characterization of transcellular transport and drug interaction of digoxin in Caco-2 cell monolayers. *Biol Pharm Bull* 28: 114-119.

Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J, Hamlin R, Keen B, Luis Fuentes V, Stepien R. 2009. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. *J Vet Intern Med* 23:1142-1150.

Chu KM, Shieh SM and Hu OY. 1995. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. *Clin Pharmacol Ther* 27: 610-621.

Felker GM and O'Connor CM. 2001. Inotropic therapy for heart failure: an evidence-based approach. *Am Heart J* 142: 393-401.

Fitton A and Brogden RN. 1994. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. *Drugs Aging* 4: 417-441.

Hagemeijer F. 1993. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. *Eur Heart J* 14: 551-566.

Haggstrom J, Boswood A, O'Grady M, Jons O, Smith S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacevic A, Rapp A, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Ronn-Landbo M, Wess G, Eggerts dottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A and DiFruscia R. 2008. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. *J Vet Intern Med* 22: 1124-1135.

Haggstrom J, Boswood A, O'Grady M, Jons O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacevic A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJL, Kvart C, French A, Ronn-Landbo M, Wess G, Eggerts dottir A, Lynne O'Sullivan M, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A and DiFruscia R. 2013^a. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril. *J Vet Intern Med* 27: 1441-1451.

Haggstrom J, Lord PF, Hoglund K, Ljungvall I, Jons O, Kvart C and Hansson K. 2013^b. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazepril in dogs with myxomatous mitral valve disease and congestive heart failure. *J Vet Intern Med* 27: 1452-1462.

Kanno N, Kuse H, Kawasaki M, Hara A, Kano R and Sasaki Y. 2007. Effects of pimobendan for mitral valve regurgitation in dogs. *J Vet Med Sci* 69: 373-377.

Kitzen JM, Lynch JJ and Driscoll EM. 1988. Cardiac electrophysiologic and hemodynamic activity of pimobendan, a new inotropic agent. *J Pharmacol Exp Ther* 244: 929-939.

Lake-Bakaar GA, Singh MK, Kass PH and Griffiths LG. 2015. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. *J Vet Cardiol* 17:120-128.

Lubsen J, Just H, Hjalmarsson AC, La Framboise D, Remme WJ, Heinrich Nols J, Dumont JM and Seed P. 1996. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the pimobendan in congestive heart failure (PICO) trial. *Heart* 76: 223-231.

Lynch JJ, Kitzen JM, Hoff PT and Lucchesi BR. 1988. Effects of pimobendan (UD-CG 115 BS), a new positive inotropic agent, on ventricular tachycardia and ischemic ventricular fibrillation in a conscious model of recent myocardial infarction. *Journal of Cardiovascular Pharmacology* 12: 547-554.

Matos JM and Glaus TM. 2010. Medical treatment of canine heart failure. *EJCAP* 20: 171-176.

McDaniel NL, Rembold CM and Murphy RA. 1994. Cyclic nucleotide dependent relaxation in vascular smooth muscle. *Can J Physiol Pharmacol* 72: 1380-1385.

O'Grady MR, Minors SL and O'Sullivan ML. 2004. Assessment of the ability of pimobendan to increase the frequency of ventricular ectopy in dogs with CHF due to DCM and chronic mitral valve insufficiency. *J Vet Intern Med* 18:452 (abstract).

Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK and DeMets DL. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. The promise study research group. *N Engl J Med* 325: 1468-1475.

Plumb DC. 2008. Plumb's veterinary drug handbook. 6th edition. Ames:Blackwell 736-738pp.

Reinker LN, Lee JA, Hovda LR and Rishniw M. 2012. Clinical signs of cardiovascular effects secondary to suspected pimobendan toxicosis in five dogs. *J Am Anim Hosp Assoc* 48: 250-255.

Rosenthal SL, Ferguson MJ, Lefbom MK and Tyrrell WD. 2006. Association of pimobendan with ventricular arrhythmias in dogs with congestive heart failure. *J Vet Intern Med* 20: 731 (abstract).

Ruegg JC. 1986. Effects of new inotropic agents on Ca⁺⁺ sensitivity of contractile proteins. *Circulation* 73: III78-III84.

Smith PJ, French AT, Van Israel N, Smith GW, Swift ST, Lee AJ, Cocoran BM and Dukes-McEwan J. 2006. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. *J Small Pract* 46: 121-130.

Steiness E and Olesen KH. 1976. Cardiac arrhythmias induced by hypokalemia and potassium loss during maintenance digoxin therapy. *Br Heart J* 38: 167-172.

Summerfield NJ, Boswood A, O'Grady MR, Gordon SG, Dukes-McEwan J, Oyama MA, Smith S, Patteson M, French AT, Culshaw GJ, Braz-Ruivo L, Estrada A, O'Sullivan ML, Loureiro J, Willis R and Watson P. 2012. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the protect study). *J Vet Intern Med* 26: 1337-1349.

Van de Water A, Verheyen J, Xhonneux R and Reneman RS. 1989. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. *J Pharmacol Methods*. 22: 207-217.

VETMEDIN® 2007. Pimobendan chewable tablets (package insert). St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.

บทคัดย่อ

การเปลี่ยนแปลงของคลื่นไฟฟ้าหัวใจในสุนัขที่เป็นโรคคลื่นหัวใจไม่ทรัลเสื่อม

ที่รักษาด้วยยาพิโนเบนเดน การศึกษาข้อมูลหังในสัตว์ป่วย 29 ตัว

สิริลักษณ์ สุรเชษฐ์พงษ์^{1,*} นิควรัตน์ บุญเลือก² ภาณร ภูพาน² วรัศริน บุญสติอนันต์² สุมณี รักไทย²
รนวน มัคคละพฤกษ์³ ศิริวรรณ สาครินทร์⁴

วัตถุประสงค์ของการศึกษาข้อมูลหังในสุนัขที่เป็นโรคคลื่นหัวใจไม่ทรัลเสื่อมที่รักษาด้วยยาพิโนเบนเดนแบบเรื่องรัง สุนัขทุกตัวมีคลื่นไฟฟ้าหัวใจปกติก่อนได้รับยา แบ่งสุนัขเป็น 2 กลุ่มตามลักษณะของคลื่นไฟฟ้าหัวใจหังได้รับยาพิโนเบนเดน ได้แก่ กลุ่มที่มีคลื่นไฟฟ้าหัวใจปกติ ($n=19$) และกลุ่มที่มีคลื่นไฟฟ้าหัวใจผิดปกติ ($n=10$) ทำการวิเคราะห์ข้อมูล ได้แก่ อายุ เพศ พันธุ์ ค่าเอนไซม์อัลคาไลน์ ฟอสฟาเตส การได้รับยาติดจากชิน ขนาดของยาพิโนเบนเดนและติดจากชินที่ได้รับต่อวัน และพารามิเตอร์ต่างๆของคลื่นไฟฟ้าหัวใจ ได้แก่ อัตราการเต้นของหัวใจ คลื่นพี ระยะพีอาร์ คลื่นคิวอาร์-เอส และระยะคิวที การศึกษาพบภาวะหัวใจเต้นผิดจังหวะเพิ่มขึ้นในสุนัขที่ได้รับยาพิโนเบนเดนร่วมกับติดจากชิน ขนาดของยาพิโนเบนเดนและติดจากชินที่ได้รับต่อวันในสุนัขที่มีคลื่นไฟฟ้าหัวใจผิดปกติสูงกว่าสุนัขที่มีคลื่นไฟฟ้าหัวใจปกติ ($p=0.022, 0.038$ ตามลำดับ) โดยสรุปภาวะหัวใจเต้นผิดจังหวะสามารถพบได้ในสุนัขที่รักษาด้วยพิโนเบนเดนแบบเรื่องรัง ดังนั้นควรระวังการให้พิโนเบนเดนในขนาดสูงหรือการให้ร่วมกับยาติดจากชิน

คำสำคัญ: หัวใจเสียจังหวะ สุนัข ติดจากชิน พิโนเบนเดน

¹ภาควิชาอายุรศาสตร์ คณะสัตวแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ปทุมวัน กรุงเทพฯ 10330

²นิสิตชั้นปีที่ 6 ปีการศึกษา 2557 คณะสัตวแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ปทุมวัน กรุงเทพฯ 10330

³คลินิกสัตว์เลี้ยงขนาดเล็กและรังสีวิทยา คณะสัตวแพทยศาสตร์ มหาวิทยาลัยเทคโนโลยีมหานคร กรุงเทพฯ 10530

⁴นิสิตปริญญาโท ปีการศึกษา 2557 ภาควิชาอายุรศาสตร์ คณะสัตวแพทยศาสตร์ ปทุมวัน กรุงเทพฯ 10330

*ผู้รับผิดชอบบทความ E-mail: sirilakd27@gmail.com